Skip to content

CT Iterative ReConstruction for Low-dose cardiopulmonary Evaluation: diagnosis of pulmonary infections in patients with febrile neutropenia - Circle Study

CT Iterative ReConstruction for Low-dose cardiopulmonary Evaluation: diagnosis of pulmonary infections in patients with febrile neutropenia - Circle Study - Circle Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON39846
Enrollment
68
Registered
2012-11-13
Start date
2013-03-26
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Febrile neutropenia neutropenic fever

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients >= 18 years - Neutropenia due to chemotherapy given for haematological disease or conditioning regimen for autologous or allogenic stem cell transplantation. Neutropenia is defined as absolute neutrophil count 38.3°C once or >= 38.0 °C longer than 1 hour) not related to administration of blood products or medication - Written informed consent

Exclusion criteria

Exclusion criteria: - Patients with a known focus of infection unrelated to the lower respiratory tract - Patients with a history of probable or proven invasive mould infection without a clinically available normalized chest CT and who use antimycotics - Previous participation in the study - Concomitant participation in a study in which the subject is exposed to X-rays - Chest X-ray made on ward (*bed-thorax*)

Design outcomes

Primary

MeasureTime frame
The main study parameters are chest X-ray, ultra low-dose CT, HRCT and consensus diagnosis. The main endpoint is sensitivity of imaging test for a pulmonary focus of febrile neutropenia as established by consensus diagnosis.

Secondary

MeasureTime frame
Secondary study parameters/endpoints are routinely obtained serum galactomannan test, bronchoalveolar lavage (BAL) and blood tests.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)